For the Inventor, By the Inventor

Enter assignee name

Shire Biochem, Inc.

Calculating rank

USPTO Granted Patents = 16

% Expired Patents = 56.3

CIPO Patents = 2

EPO Patents = 1

Forward Citations = 129

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Songchun Jiang (3 out of 16 patents)

Giorgio Attardo (3 out of 19 patents)

Nghe Nguyen-Ba (3 out of 28 patents)

4. Sui Xiong Cai (3 out of 87 patents)

5. Qing Yu (3 out of 3 patents)

6. Francis J Giles (3 out of 6 patents)

7. Hong Zhang (2 out of 30 patents)

8. Robert F Rando (2 out of 16 patents)

9. Richard Storer (2 out of 9 patents)

10. Jacques Jolivet (2 out of 2 patents)

11. William E Kemnitzer (2 out of 6 patents)

12. Dragos Vizitiu (1 out of 8 patents)

13. Boulos Zacharie (1 out of 29 patents)

14. Jean-Eric Lacoste (1 out of 5 patents)

15. Serge Lamothe (1 out of 6 patents)

16 patents: Sort by Forward Citations

1. 7528164 - Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof (2009-05-05),

2. 7501514 - Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides (2009-03-10),

3. 7476741 - Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof (2009-01-13),

4. 7465465 - Pharmaceutical formulation comprising lanthanum compounds (2008-12-16),

5. 7442813 - Process for producing dioxolane nucleoside analogues (2008-10-28),

6. 7230100 - Stereoselective method for the preparation of nucleosides (2007-06-12),

7. 7122693 - Acetaldehyde acetal compounds, their synthesis, and uses thereof (2006-10-17),

8. 7109334 - Stereoselective methods for the preparation of nucleosides (2006-09-19),

9. RE39155 - Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B (2006-07-03),

10. 7015328 - Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2006-03-21),

11. 6964968 - Method for the treatment or prevention of viral infection using nucleoside analogues (2005-11-15),

12. 6960594 - Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer (2005-11-01),

13. 6887879 - Pharmaceutical combination of antiviral agents (2005-05-03),

14. 6831174 - Processes for preparing substituted 1, 3-oxathiolanes with antiviral properties (2004-12-14),

15. 6800639 - Pharmaceutical combination for the treatment of cancer (2004-10-05),

Company Overview

Shire Biochem, Inc. is a biotechnology company based in California, specializing in the development and manufacturing of innovative biopharmaceuticals. The organization focuses on advancing therapies for rare diseases, particularly in the fields of enzyme replacement therapy and gene therapy. With a commitment to addressing unmet medical needs, Shire Biochem leverages cutting-edge research and technology to create solutions that improve patient outcomes and enhance quality of life for individuals with complex health conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

16 Patents

#46 in

#933 in Canada

#37,887 in the World

Shire Biochem, Inc.

Forward Citations = 129

41 inventors:

Songchun Jiang (3 out of 16 patents)

Giorgio Attardo (3 out of 19 patents)

Nghe Nguyen-Ba (3 out of 28 patents)

4. Sui Xiong Cai (3 out of 87 patents)

5. Qing Yu (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Shire Biochem, Inc.. Retrieved from https://idiyas.com/company/shire-biochem

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…